Velocity Pharmaceutical Development, LLC ("VPD"), a company that creates, invests in, and manages a portfolio of project focused companies, each of which contains a single drug candidate acquired from a third party, today announced that David J. Collier, MD, the company's Chief Executive Officer, will moderate a panel discussion at the seventh annual BioPharm America International Partnering Conference, to be held September 22-24 in Boston, MA. The BioPharm America conference is one of the premier international partnering conferences with 550 companies from 35 countries participating in last year's event.
Dr. Collier will be chairing a session entitled "How Unconventional Pharma and VC Collaborations are Expanding R&D Budgets" on September 22nd. Panelists for the session include David Barry, MD, PhD (Flagship Ventures), David Grayzel, MD (Atlas Venture), Jay Lichter, PhD (Avalon Ventures), Kareem Reda (Celgene Corporation) and Rob Armstrong, PhD (Gelesis, Inc.) This panel of industry experts will explore how pharma companies and VC firms are partnering to develop drugs and generate attractive investment returns.
VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net.